Chugai And Riken Bio Venture Company To Research Antibody Drugs
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical and Chiome Bioscience, a biopharmaceutical venture company established by Riken Institute, announced Dec. 3 that the two will jointly identify monoclonal antibodies against multiple targets selected from a series of disease-associated proteins provided by Chugai. The research will use an autonomously diversifying library system developed by Chiome. Chugai will give Chiome a undisclosed one-time payment and milestone compensations according to research results. (Click here for more - Japanese language